



ASX ANNOUNCEMENT

4 July 2022

Cleansing Statement

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) advises that on 30 June 2022, it issued a total of 50,000 Fully Paid Ordinary Shares (the **Securities**) without disclosure to the recipients under Part 6D.2 of the Corporations Act 2001 (Cth) (the **Corporations Act**). The Company also notes that on the same day it also issued a total of 1,300,000 employee options under CardieX's Performance Rights and Option Plan (ESOP), approved at the Company's 2020 Annual General Meeting.

The Company hereby gives notice under Section 708A(5) of the Corporations Act that:

- (a) the Company has issued the Securities without disclosure to the recipients under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with the provisions of:
 - a. Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
- (c) As at the date of this notice there is no information
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
 - ii. the rights and liabilities attaching to the relevant securities.

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Authorised for release by the Board of Directors, and released by Jarrod White



For more information please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com

About CardieX

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR-X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2022 launch).